ADIAL PHARMACEUTICALS INC (ADIL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.12+6.91%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ADIL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ADIL — legal / regulatory event — Notice of Delisting or Failure to
Dated 2026-08-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 18, 2026, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued…
Why it matters: Managing money well is key for ADIL's stability. Changes can affect future growth.
Worry ifAn announcement will share a clear plan for capital allocation.
Less concerning ifThere is unclear information or bad news about finances.
Why it matters: A final deal would help AD04 reach more markets in Europe. This could boost growth.
Supportive ifA final deal with Molteni Farmaceutici for AD04 in Europe will be shared.
Worry ifNo deal was made with Molteni Farmaceutici or there is a big delay in talks.
Why it matters: How ADIL manages its debts affects its money and stability.
Worry ifLook for good news about managing debts and money allocation.
Less concerning ifBad news about debts or money management could be coming.
Why it matters: It is important to track cash levels after the $64 million financing. This ensures stability.
Worry ifCash and cash equivalents will be over $4.6 million in the next financial update.
Less concerning ifCash and cash equivalents will be below $4.6 million in the next financial update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$366 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $879 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,702 loss on $10,000 · 87.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Changes in FDA policy could speed up AD04's path to market and affect timelines.
Supportive ifFDA supports AD04's approval based on one key trial and extra evidence.
Worry ifFDA keeps the usual rules of two key trials for AD04 approval.
Why it matters: A deal with Molteni could help growth and reach more customers.
Supportive ifAn announcement will explain the details and benefits of the Molteni deal.
Worry ifNo progress or updates on the partnership with Molteni for several months.
Why it matters: Updates on cash will show if Adial can pay for its work and trials.
Worry ifCash and cash equivalents were over $4.6 million before Q2 earnings.
Less concerning ifCash and cash equivalents were below $4.6 million before Q2 earnings.
Why it matters: Completing this acquisition is key for growth and could boost investor confidence.
Supportive ifA press release will confirm the Azora acquisition is complete.
Worry ifThere may be delays or problems with the Azora acquisition.
Why it matters: Filing the IND is important. It helps move AT177 into clinical trials for ulcerative colitis.
Supportive ifThe company files the IND for AT177 by the end of Q1 2027.
Worry ifThe IND filing is delayed beyond the first half of 2027.
Why it matters: Approval is needed to change preferred stock to common stock. This affects financing and equity structure.
Supportive ifStockholders approve the conversion of Series A preferred stock to common stock.
Worry ifStockholders reject the change of Series A preferred stock.
Why it matters: Fixing the Nasdaq delisting notice is important. It helps keep the company's stock listing.
Worry ifThe company fixes the Nasdaq notice. It meets the minimum equity requirement of $2.5 million.
Less concerning ifThe company does not fix the Nasdaq notice. This may lead to delisting.
Why it matters: Starting the Phase 1 trial is important. It will test AT177 as a treatment for ulcerative colitis.
Supportive ifThe company initiates the Phase 1 clinical trial for AT177 in the second half of 2027.
Worry ifThe initiation of the Phase 1 trial is postponed beyond late 2027.